

**Joint Educational Training Programme:  
"Antithrombotic Therapies: Clinical challenges and future directions"**

---

12-14 June 2019, European Heart House, Sophia Antipolis - France

## **The Background & the Project**

---

Following the webinar series "Updates in antithrombotic therapy for cardiovascular diseases", the ESC Working Group on Aorta and Peripheral Vascular Diseases (WG on Aorta & PVD) and the ESC Working Group on Thrombosis (WG on Thrombosis) are renewing their collaboration to propose a course on **Antithrombotic Therapies: Clinical challenges and future directions** to be held at the European Heart House.

This Educational Training Programme (ETP) is designed to educate and update Health Care Professionals' scientific knowledge and provide practical tips for their daily practice with the help of leading experts, with a special focus on current unmet therapeutic needs, recent evidence from large randomized clinical trials as well as the innovative aspects of the recently released ESC guidelines (if applicable).

The programme will feature 4 main areas which will be addressed from both WGs' perspective. These 4 main areas will include:

- Interactions between endothelium and primary/secondary haemostasis
- Antithrombotic in special populations (including diabetes, obesity, elderly and frailty, pregnancy)
- Combined antithrombotic strategies in Atherothrombotic diseases (stable versus unstable, AF, PAD, short and long term)
- Treatment and secondary prevention of Venous thromboembolism (in the general population and in cancer patients)

## **Scientific Coordinator / Contributors**

---

Topics of the course are discussed and approved by Nuclei of the ESC WG on Aorta & PVD and the ESC WG on Thrombosis.

## **Learning objectives**

---

**8 sessions** in the Educational Training Programme aiming at:

- Understanding clinically-relevant mechanisms of action (haemostatic and pharmacological) underlying the most recent and effective combined antithrombotic strategies in atherothrombotic and venous thromboembolic diseases
- Managing atherothrombotic diseases in the chronic and acute settings, in special patient populations such as diabetic, chronic kidney disease, pregnant, obese, older and/or frail patients who remain an unmet clinical need in spite of the most recent evidence
- Managing cardioembolic and venous thromboembolic diseases in the chronic and/or acute settings, with a special focus on cancer patients

The ESC will submit the Educational Training Programme to the UEMS-EACCME for accreditation. The European Accreditation Council for Continuing Medical Education (EACCME) is an institution of the European Union of Medical Specialists (UEMS) responsible for the evaluation and accreditation of Medical Education Programmes.

**Joint Educational Training Programme:  
"Antithrombotic Therapies: Clinical challenges and future directions"**

---

12-14 June 2019, European Heart House, Sophia Antipolis - France

**Preliminary list of Faculties**

---

Working Group on Aorta (WGA)

1. Victor Aboyans- Chair
2. Marco De Carlo- Past-Chair
3. Lucia Mazzolai- Vice-Chair
4. Oliver Schlager- Treasurer
5. Marianne Brodmann
6. Christine Espinola-Klein
7. José Rodriguez-Palomares,
8. Emmanuel Messas
9. Charalambos Vlachopoulos

Working Group on Thrombosis (WGT)

1. Dirk Sibbing- Chair
2. Bianca Rocca- Past-Chair
3. Gemma Vilahur- Vice-Chair
4. Andrea Rubboli- Treasurer
5. Diana Gorog
6. Rob Storey
7. Jean Philippe Collet
8. Joao Morais
9. Tobias Geisler

Special guest: Lars Wallentin

**Preliminary Programme**

---

**All sessions have 4 speakers with 20min per talk and 10min of common final discussion**

**Day 1**

13:00-14:30 Registrations

14:30-14:50 **Welcome message from the WG Chairpersons.**

*V Aboyans and D Sibbing*

14:50-16:20: **Session 1 - Focus on the pathophysiology of endothelium and haemostasis / thrombosis**

Chairs: *V Aboyans and D Sibbing*

- 1- Factor Xa: a crossroad between coagulation and platelet. *T Geisler #3*
- 2- Endothelial function and biomarkers in PAD. *C Vlachopoulos*
- 3- Platelets and atherothrombosis. *B Rocca#1*
- 4- Novel targets in the coagulation pathway. *D Gorog*

16:20-16:45: Networking

**Joint Educational Training Programme:  
"Antithrombotic Therapies: Clinical challenges and future directions"**

---

12-14 June 2019, European Heart House, Sophia Antipolis - France

16.45-18.15: **Session 2 - Antithrombotic therapies and cardiovascular devices** day 3 1st morning

Chairs: *L Mazzolai and T Geisler  
Vlachopoulos*

- 1- PFO closure: indications and antithrombotic strategy after implantation. *JP Collet*
- 2- Left atrial appendage occlusion: indications and antithrombotic strategy thereafter. *A Rubboli*
- 3- TAVI, SAVI and antithrombotic strategies thereafter. *D Sibbing*
- 4- Aortic diseases, TEVAR, EVAR and antithrombotic strategies. *J Rodriguez-Palomares*

18.30-19.00: **Lecture - Antithrombotic therapies: how to assess the bleeding risk and its severity?**

Chairs: *V Aboyans and D Sibbing*

Lars Wallentin

19.00-20.30: Networking at the Heart House

## **Day 2**

### **Morning sessions - Focus on: Antithrombotic strategies in special populations**

**9:00-10:30: Session 1 - Antithrombotic therapies in special populations** day 2, late morning

Chairs: *D Gorog and M De Carlo*

- 1- Antithrombotic therapies in acquired & congenital thrombophilic disorders? *L Mazzolai*
- 2- Antithrombotic therapies in pregnancy. *M Brodmann*
- 3- Antithrombotic therapies in CKD. *D Gorog*
- 4- Antithrombotic therapies in the old/frail patients. *E Messas*

10:30-11:00: Networking

**11:00-12:30: Session 2 - Antithrombotic therapies and diabetes and/or metabolic syndrome**

Chairs: *M Brodmann and B Rocca*

- 1- The haemostatic imbalance in type 2 diabetes and Metabolic Syndrome. *G Vilahur*
- 2- Antithrombotic strategies in diabetic patients with CAD. *M De Carlo*
- 3- Antithrombotic strategies in diabetic patients with PAD. *C Espinola-Klein*
- 4- Obesity and antithrombotic strategies in arterial and venous diseases. *R Storey*

12:30-14:00: Networking

**Joint Educational Training Programme:  
"Antithrombotic Therapies: Clinical challenges and future directions"**

---

12-14 June 2019, European Heart House, Sophia Antipolis - France

**Day 2**

**Afternoon sessions - Focus on: combined antithrombotic strategies in Atherothrombotic diseases (stable vs unstable, AF, PAD, short and long term)**

14:00-15:30: **Session 1 - Combined antithrombotic strategies in CAD**

Chairs: *D Sibbing and T Geisler*

day 2, early morning

- 1- Update on DAPT in the first year after ACS. *JP Collet* **Rob Storey**
- 2- Dual antithrombotic strategy in stable CAD: for whom? *D Sibbing*
- 3- Antithrombotic and antiplatelet agents one year post-MI: how many options?  
*R Storey Tobias Geisler*
- 4- Atrial Fibrillation in stable CAD and ACS). *A Rubboli*

15.30-16:00: Networking

16:00-17:30: **Session 2 - Combined antithrombotic strategies in PAD** day 1 afternoon session 2

Chairs: *J Rodriguez-Palomares and O Schlager*

- 5- DAPT after peripheral revascularization. *M De Carlo*
- 6- AF & PAD: a non-random association. *V Aboyans*
- 7- Dual antithrombotic therapies in stable patients with PAD. *C Espinola-Klein*
- 8- Assessment of bleeding risk under antithrombotic therapies. *JP Collet Lucia Mazzolai*

17:30-18:00: Networking

18:00-18:40: **Debate Session - Antithrombotic strategies in asymptomatic patients:  
Pros and Cons**

Chairs: *J Morais and C Vlachopoulos*

18:00-18:15: Antithrombotic therapy is indicated in Primary Prevention (pro). *B Rocca*

18:15-18:30: Antithrombotic therapy is indicated in Primary Prevention (contra). *V Aboyans*

18:30-18:35: Rebuttal. *B Rocca*

18:35-18:40: Rebuttal. *V Aboyans*

18:40: Wrap up

**Joint Educational Training Programme:  
"Antithrombotic Therapies: Clinical challenges and future directions"**

---

12-14 June 2019, European Heart House, Sophia Antipolis - France

**Day 3**

**Morning sessions - Focus on: Treatment and secondary prevention of venous thromboembolism in the general population and in cancer patients**

take away the title

09:00-10:30: **Session 1**

Chairs: *A Rubboli and E Messas*

- 9- Prevention of VTE: when and how? Joao Morais
- 10- PE, DVT and SVT: current management. M Brodmann
- 11- Long-term anticoagulation after PE/DVT: when and how? C Espinola-Klein
- 12- Prevention and treatment of post-thrombotic syndrome. O Schlager

10:30-10:45: Networking

10:45-12:15: **Session 2**

Chairs: *C Espinola-Klein and G Vilahur*

4 speakers 20 min +10 common discussion at the end

- 1- Haemostasis and thrombosis in cancer. *G Vilahur*
- 2- Coronary and stroke events in patients with cancer. *J Morais*
- 3- Management of VTE in patients with cancer. *O Schlager*
- 4- Looking for cancer after VTE? When and how? *E Messas*

12:15-12:30: Closing remarks *V Aboyans and G Vilahur*